Food and Drug Administration

Science Board to the Food and Drug Administration

April 22, 2004

Slides

Overview of the FDA Initiative on Obesity, Dr. Robert Brackett, PhD, FDA (HTM) (PPT)

FDA 2004: Toward New Therapeutics for Obesity, Dr. David Orloff, MD, FDA (HTM) (PPT)

Obesity Research, David Acheson, FDA (HTM) (PPT)

FDA Obesity Working Group, Alan Rulis (HTM) (PPT)

FDA's "Critical Path" Initiative, Dr. Janet Woodcoek, MD, FDA (HTM) (PPT)

Public Comment on Behalf of AIDS Vaccine Advocay Coalition and the San Franisco AIDS Foundation, Robert Reinhard (PDF)

Developing Chronic Disease Therapies, Dr. Robert Califf, MD, Duke Clinical Research Institute (PPT)

ORA Science Peer Review - Pesticide and Industrial Chemical Programs, John Marzilli , FDA (HTM) (PPT)

Presentation by Robert Langer, FDA (HTM) (PPT)

The Critical Path Opportunities for Efficiency in Development, Dr. Robert Temple, MD, FDA (HTM) (PPT)

FDA's Critical Path to New Medical Product Development, Dr. Larry Kessler, ScD, FDA (HTM) (PPT)

Critical Path: Overview of Selected Ongoing CBER Efforts and Future Opportunities, Dr. Jesse Goodman, MD, MPH, FDA (HTM) (PPT)

Written Testimony on The Critical Path White Paper, AdvaMed (PDF)

Frequency Distributions of Weight Loss Response for Placebo and Capsule 1.5mg, Dr. Allen Roses, MD (HTM) (PPT)